Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...
"China has found a balance in the global healthcare 'impossible triangle' of high quality, affordability, and short wait ...
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S.
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...
Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...
ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...
FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...
Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...
Seasoned clinical development leader brings more than 25 years of deep expertise in clinical development and operations across biotech and ...
Khaleej Times on MSN
Novartis deepens commitment to the UAE as pharmaceutical market set to double by 2033
The UAE is rapidly consolidating its position as a global pharmaceutical and life sciences hub, with the national market ...
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Ja ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results